Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 192

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma

Open access
Avet-Loiseau, Hervé, Davies, Faith E., Samur, Mehmet K., Corre, Jill, D'Agostino, Mattia, Kaiser, Martin F., Raab, Marc S., Weinhold, Niels, Gutierrez, Norma C., Paiva, Bruno, Neri, Paola, Weisel, Katja, Maura, Francesco, Walker, Brian A., Bustoros, Mark, Stewart, A. Keith, Usmani, Saad Z., Hillengass, Jens, Chng, Wee Joo, Keats, Jonathan J., Martinez-Lopez, Joaquin, Sperling, Adam S., Touzeau, Cyrille, Zhan, Fenghuang, Raje, Noopur S., Cavo, Michele, Bolli, Niccolò, Ghobrial, Irene M., Dhodapkar, Madhav V., Jagannath, Sundar, Spencer, Andrew, Parekh, Samir, Bahlis, Nizar J., Lonial, Sagar, Sonneveld, Pieter, Bergsagel, Leif, Orlowski, Robert Z., Morgan, Gareth, Mateos, María Victoria, Rajkumar, S. Vincent, San Miguel, Jesus F., Anderson, Kenneth C., Moreau, Philippe, Kumar, Shaji, Prósper, Felipe, Munshi, Nikhil C. · 2025 · Journal of Clinical Oncology

Abstract

Despite significant improvements in survival of patients with multiple myeloma (MM), outcomes remain heterogeneous, and a significant proportion of patients experience suboptimal outcomes. Importantly, traditional prognostic factors based on data from patients treated with older therapies no longer capture prognosis accurately in the contemporary era of novel triplet or quadruplet therapies. Therefore, risk stratification requires refinement in the context of available and investigational treatment options in routine practice and clinical trials, respectively. The current identification of high-risk MM (HRMM) in routine practice is based on the Revised International Staging System, which stratifies patients using a combination of widely available serum biomarkers and chromosomal abnormalities assessed via fluorescence in situ hybridization. In recent years, a substantial body of evidence concerning additional clinical, biological, and molecular/genomic prognostic factors has accumulated, along with new MM risk stratification tools and consensus reports. The International Myeloma Society, along with the International Myeloma Working Group, convened an Expert Panel with the primary aim of revisiting the definition of HRMM and formulating a practical and data-driven consensus definition, based on new evidence from molecular/genomic assays, updated clinical data, and contemporary risk stratification concepts. The Panel proposes the following Consensus Genomic Staging (CGS) of HRMM which relies upon the presence of at least one of these abnormalities: (1) del(17p), with a cutoff of >20% clonal fraction, and/or TP53 mutation; (2) an IgH translocation including t(4;14), t(14;16), or t(14;20) along with 1q+ and/or del(1p32); (3) monoallelic del(1p32) along with 1q+ or biallelic del(1p32); or (4) β2 microglobulin ≥5.5 mg/L with normal creatinine (<1.2 mg/dL).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco-24-01893

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Metadata

Authors
Avet-Loiseau, H., Davies, F. E., Samur, M. K., Corre, J., D'Agostino, M., Kaiser, M. F., Raab, M. S., Weinhold, N., Gutierrez, N. C., Paiva, B., Neri, P., Weisel, K., Maura, F., Walker, B. A., Bustoros, M., Stewart, A. K., Usmani, S. Z., Hillengass, J., Chng, W. J., Keats, J. J., Martinez-Lopez, J., Sperling, A. S., Touzeau, C., Zhan, F., Raje, N. S., Cavo, M., Bolli, N., Ghobrial, I. M., Dhodapkar, M. V., Jagannath, S., Spencer, A., Parekh, S., Bahlis, N. J., Lonial, S., Sonneveld, P., Bergsagel, L., Orlowski, R. Z., Morgan, G., Mateos, M. V., Rajkumar, S. V., San Miguel, J. F., Anderson, K. C., Moreau, P., Kumar, S., Prósper, F., & Munshi, N. C.
Venue
Journal of Clinical Oncology
Published
2025-08-20
Volume
43
Issue
24
Pages
2739-2751
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W4411141147
Cited by
192
References
12
FWCI
122.96
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma. https://app.cochat.ai/papers/10.1200/jco-24-01893
The paper
Avet-Loiseau, H., Davies, F. E., Samur, M. K., Corre, J., D'Agostino, M., Kaiser, M. F., Raab, M. S., Weinhold, N., Gutierrez, N. C., Paiva, B., Neri, P., Weisel, K., Maura, F., Walker, B. A., Bustoros, M., Stewart, A. K., Usmani, S. Z., Hillengass, J., Chng, W. J., . . . Munshi, N. C. (2025). International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma. Journal of Clinical Oncology. https://doi.org/10.1200/jco-24-01893

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.